摘要
Abstract
Objective To investigate the clinical value of trastuzumab combined with pertuzumab and capecitabine in the treatment of patients with advanced human epidermal growth factor receptor 2(HER2)-positive breast cancer.Methods A total of 92 patients with advanced HER2-positive breast cancer admitted to Kaifeng Central Hospital from August 2023 to April 2025 were enrolled.According to different treatment regimens,they were divided into a control group(n=46),which received the standard clinical regimen(trastuzumab+docetaxel),and a study group(n=46),which received trastuzumab combined with pertuzumab plus capecitabine.Differences between the two groups were analyzed in terms of breast cancer-related clinical indicators,therapeutic efficacy,and incidence of adverse reactions.Results Before treatment,there were no significant differences between the two groups in the levels of HER2 and carbohydrate antigen 15-3(CA15-3)(P＞0.05).After 6 treatment cycles,the levels of HER2 and CA15-3 decreased in both groups compared with those before treatment,and the levels in the study group were lower than those in the control group,with statistically significant differences(P＜0.05).The objective response rate(ORR)and disease control rate(DCR)in the study group were higher than those in the control group,with statistically significant differences(P＜0.05).The incidence of adverse reactions in the study group was lower than that in the control group,with statistically significant differences(P＜0.05).Conclusion For patients with HER2-positive breast cancer,trastuzumab combined with pertuzumab and capecitabine shows favorable clinical value.It can improve breast cancer-related clinical indicators,enhance therapeutic efficacy,and reduce chemotherapy-related adverse reactions,and therefore has clinical application value.关键词
人表皮生长因子受体2/曲妥珠单抗/帕妥珠单抗/卡培他滨/乳腺癌Key words
human epidermal growth factor receptor 2/trastuzumab/pertuzumab/capecitabine/breast cancer分类
医药卫生
